Parkway Life Real Estate Investment Trust

OTCPK:PRKW.F Stock Report

Market Cap: US$2.0b

Parkway Life Real Estate Investment Trust Valuation

Is PRKW.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PRKW.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PRKW.F ($3) is trading below our estimate of fair value ($6.7)

Significantly Below Fair Value: PRKW.F is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for PRKW.F?

Key metric: As PRKW.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for PRKW.F. This is calculated by dividing PRKW.F's market cap by their current earnings.
What is PRKW.F's PE Ratio?
PE Ratio26.9x
EarningsS$98.54m
Market CapS$2.65b

Price to Earnings Ratio vs Peers

How does PRKW.F's PE Ratio compare to its peers?

The above table shows the PE ratio for PRKW.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average34.4x
LTC LTC Properties
17.4x-4.7%US$1.8b
SILA Sila Realty Trust
64.1x8.4%US$1.4b
NHI National Health Investors
27.6x10.8%US$3.5b
STRW Strawberry Fields REIT
28.6x110.2%US$634.9m
PRKW.F Parkway Life Real Estate Investment Trust
26.9x18.4%US$2.7b

Price-To-Earnings vs Peers: PRKW.F is good value based on its Price-To-Earnings Ratio (26.9x) compared to the peer average (34.4x).


Price to Earnings Ratio vs Industry

How does PRKW.F's PE Ratio compare vs other companies in the Global Health Care REITs Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
PRKW.F 26.9xIndustry Avg. 27.2xNo. of Companies5PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: PRKW.F is expensive based on its Price-To-Earnings Ratio (26.9x) compared to the Global Health Care REITs industry average (26.7x).


Price to Earnings Ratio vs Fair Ratio

What is PRKW.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PRKW.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio26.9x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate PRKW.F's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PRKW.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$3.00
US$3.53
+17.7%
8.2%US$3.82US$3.05n/a4
Nov ’25US$2.80
US$3.50
+25.1%
9.2%US$3.87US$3.02n/a4
Oct ’25US$3.26
US$3.51
+7.6%
12.5%US$3.93US$2.80n/a4
Sep ’25n/a
US$3.22
0%
9.8%US$3.50US$2.69n/a4
Aug ’25n/a
US$3.22
0%
9.8%US$3.50US$2.69n/a4
Jul ’25US$2.56
US$3.28
+28.0%
11.8%US$3.76US$2.68n/a4
Jun ’25n/a
US$3.28
0%
11.8%US$3.76US$2.68n/a4
May ’25US$2.35
US$3.28
+39.4%
11.8%US$3.76US$2.68n/a4
Apr ’25US$2.52
US$3.36
+33.3%
9.6%US$3.80US$2.89n/a4
Mar ’25US$2.53
US$3.33
+31.6%
11.1%US$3.77US$2.87n/a3
Feb ’25US$2.40
US$3.24
+35.0%
11.4%US$3.61US$2.87n/a2
Jan ’25n/a
US$3.17
0%
8.2%US$3.51US$2.82n/a4
Dec ’24US$2.67
US$3.17
+18.8%
8.2%US$3.51US$2.82n/a4
Nov ’24n/a
US$3.17
0%
8.2%US$3.51US$2.82US$2.804
Oct ’24n/a
US$3.23
0%
7.9%US$3.51US$2.82US$3.264
Sep ’24n/a
US$3.29
0%
5.6%US$3.53US$3.01n/a4
Aug ’24n/a
US$3.35
0%
5.6%US$3.59US$3.06n/a4
Jul ’24n/a
US$3.35
0%
5.1%US$3.58US$3.05US$2.565
Jun ’24US$2.77
US$3.36
+21.4%
5.1%US$3.59US$3.06n/a5
May ’24US$2.70
US$3.36
+24.3%
5.1%US$3.59US$3.06US$2.355
Apr ’24US$2.75
US$3.39
+23.2%
5.7%US$3.58US$3.05US$2.525
Mar ’24n/a
US$3.39
0%
5.7%US$3.58US$3.05US$2.535
Feb ’24n/a
US$3.40
0%
5.6%US$3.64US$3.11US$2.404
Jan ’24n/a
US$3.30
0%
8.8%US$3.74US$3.02n/a4
Dec ’23US$2.70
US$3.32
+23.0%
8.0%US$3.58US$2.92US$2.674
Nov ’23n/a
US$3.32
0%
8.0%US$3.58US$2.92n/a4

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies